Glutargin Versus Arginine for Hyperammonemia in Chronic Liver Diseases: A Randomized Controlled Trial

Miao Hao,Wenjun Wang,Juanjuan Shi,Yaping Li,Mei Li,Guo-ying Pan,Xiaoli Jia,Jinhui Yang,Shuangsuo Dang,Xin Zhang
DOI: https://doi.org/10.25236/ijfm.2023.051003
2023-01-01
Abstract:To investigate the efficacy and safety of glutargin versus arginine in the treatment of hyperammonemia in patients with chronic liver diseases, we screened consecutive patients aged 18 to 65 years with chronic liver diseases between February 2007 and October 2010 at two hepatology centers in China. The level of blood ammonia in eligible patients was at least 1.2 times the upper limit of normal. Enrolled patients were randomly assigned at a 1:1 ratio to receive either 20 g of glutargin or 20 g of arginine for 7 days. The primary outcome was the efficacy rate in lowering the levels of blood ammonia. Finally a total of 80 patients were enrolled in this study. In the intention-to-treat analysis, glutargin did not show a superior efficacy rate to arginine in lowering the levels of blood ammonia (75% in the glutargin group and 80% in the arginine group, P=0.57). The decrease in blood ammonia level was also similar in the glutargin group and the arginine group (41% versus 40%, P=0.59). Per-protocol analyses showed similar results. However, the overall symptom and sign scores decreased more in the glutargin group than in the arginine group (P=0.058 in the intention-to-treat analysis and P=0.014 in the per-protocol analysis, respectively). The incidence of adverse events was similar in the two groups. Conclusion: Glutargin shows similar efficacy to arginine in the treatment of hyperammonemia in patients with chronic liver diseases. However, glutargin is superior to arginine in improving symptoms and signs.
What problem does this paper attempt to address?